| Name | PRI-724 |
| Description | PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction. |
| In vitro | METHODS: CAL27 and FaDu cells were treated with HS-173, erlotinib, and PRI-724 (0-100 μM, 48 hours), and cell viability was analyzed by resazurin assay.
RESULTS The combination of PRI-724 and HS-173 synergistically reduced the viability of FaDu cells; in CAL27 cells, the best inhibitory results were observed with the mixture of PRI-724 and erlotinib. [2] |
| In vivo | METHODS: HCV transgenic mice were treated with PRI-724 (5, 20 mg/kg, intraperitoneally, once a day, for 6 weeks) intraperitoneally, and the antifibrotic activity of PRI-724 against HCV-induced liver fibrosis was evaluated.
RESULTS In HCV transgenic mice, the expression of S100A4, which is controlled by CBP/β-catenin, was increased; this induction was attenuated by the administration of PRI-724, and the HCV-induced increase in hepatic hydroxyproline was also attenuated. Inhibition of CBP/β-catenin by PRI-724 is effective against HCV-induced liver fibrosis. [1]
METHODS: HCV transgenic mice were treated with PRI-724 (0.1, 0.3, 1 mg/kg, subcutaneous injection, 6 weeks) to evaluate the anti-fibrotic activity of PRI-724.
RESULTS PRI-724 can effectively reduce the area of collagen fibers in the liver in a dose-dependent manner and increase the expression level of Mmp8 mRNA and the number of F4/80, Ly-6C and Gr-1 positive cells. [1] |
| Storage | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (83.51 mM)
Ethanol : 1.8 mg/mL (2.7 mM)
|
| Keywords | PRI724 | PRI-724 | PRI 724 |
| Inhibitors Related | Urea | Wnt pathway activator 1 | L-quebrachitol | MSAB | EMT inhibitor-1 | Wogonin | CHIR-99021 | XAV-939 | (E)-Ferulic acid | Nefopam hydrochloride | KY-05009 | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
